New data suggests that retatrutide, a dual-action medication, might represent a significant advance in body management. This therapy combines the actions of a GLP-1 receptor and a GIP agonist , seemingly offering a more impact than current approaches . Patient assessments have shown promising outcomes, including substantial reductions in size and